

Supplementary Table 1. Age-stratified HI antibody responses to A/H3N2 and B/Brisbane in the per-protocol immunogenicity cohort (Day 0 and Day 28) and the per-protocol immunogenicity persistence cohort (Month 6)

	Time point	N	6 months–9 years	N	6–11 months	N	12–35 months	N	3–9 years	N	10–17 years	
A/Victoria/210/2009 (H3N2)												
SPR, % (95% CI)	Day 0	65	46.2%	7	0.0%	35	48.6%	23	56.5%	33	36.4%	
			(33.7–59.0)		(0.0–41.0)		(31.4–66.0)		(34.5–76.8)		(20.4–54.9)	
	Day 28	65	100.0%	7	100.0%	35	100.0%	23	100.0%	33	100.0%	
			(94.5–100.0)		(59.0–100.0)		(90.0–100.0)		(85.2–100)		(89.4–100.0)	
	Month 6	56	100.0%	6	100.0%	28	100.0%	22	100.0%	35	97.1%	
			(93.6–100.0)		(54.1–100.0)		(87.7–100.0)		(84.6–100.0)		(85.1–99.9)	
SCR, % (95% CI)	Day 28	65	98.5%	7	100.0%	35	100.0%	23	95.7%	33	87.9%	
			(91.7–100.0)		(59.0–100.0)		(90.0–100.0)		(78.1–99.9)		(71.8–96.6)	
	Month 6	56	82.1%	6	100.0%	28	78.6%	22	81.8%		85.7%	
			(69.6–91.1)		(54.1–100.0)		(59.0–91.7)		(59.7–94.8)		(69.7–95.2)	
	GMT, value (95% CI)	Day 0	65	20.8	7	5.0	35	21.2	23	31.0	33	20.0
				(15.2–28.3)		(5.0–5.0)		(13.7–32.8)		(19.0–50.5)		(13.0–30.8)
Day 28		65	396.3	7	88.4	35	448.3	23	518.6	33	279.2	
			(276.3–568.5)		(35.9–217.6)		(265.9–755.8)		(304.1–884.3)		(202.1–385.8)	
Month 6		56	186.8	6	127.0	28	160.0	22	252.7	35	160.1	
			(152.9–228.2)		(70.1–230.0)		(119.1–214.8)		(186.3–342.8)		(118.1–217.0)	
B/Brisbane/60/2008												

	Time point	N	6 months–9 years	N	6–11 months	N	12–35 months	N	3–9 years	N	10–17 years
SPR, % (95% CI)	Day 0	65	21.5%	7	28.6%	35	14.3%	23	30.4%	33	39.4%
			(12.3–33.5)		(3.7–71.0)		(4.8–30.3)		(13.2–52.9)		(22.9–57.9)
	Day 28	65	96.9%	7	100.0%	35	100.0%	23	91.3%	33	100.0%
			(89.3–99.6)		(59.0–100.0)		(90.0–100.0)		(72.0–98.9)		(89.4–100.0)
	Month 6	56	92.9%	6	100.0%	28	92.9%	22	90.9%	33	94.3%
			(82.7–98.0)		(54.1–100.0)		(76.5–99.1)		(70.8–98.9)		(80.8–99.3)
SCR, % (95% CI)	Day 28	65	84.6%	7	100.0%	35	85.7%	23	78.3%	33	84.8%
			(73.5–92.4)		(59.0–100.0)		(69.7–95.2)		(56.3–92.5)		(68.1–94.9)
	Month 6	56	75.0%	6	83.3%	28	78.6%	22	68.2%	35	82.9%
			(61.6–85.6)		(35.9–99.6)		(59.0–91.7)		(45.1–86.1)		(66.4–93.4)
GMT, value (95% CI)	Day 0	65	17.4	7	16.4	35	15.1	23	21.9	33	22.2
			(13.2–22.8)		(3.7–71.9)		(10.6–21.5)		(14.0–34.1)		(14.7–33.5)
	Day 28	65	160.9	7	176.8	35	142.2	23	188.8	33	320.1
			(115.0–225.2)		(28.1–1111.2)		(93.5–216.2)		(103.7–343.8)		(216.8–472.6)
	Month 6	56	154.1	6	302.0	28	148.4	22	134.5	35	242.4
			(115.3–205.9)		(115.6–788.8)		(97.9–225.1)		(82.2–220.1)		(173.9–337.8)

CI, confidence interval; N, number of subjects in group; HI, hemagglutination-inhibition; GMT, geometric mean titer; SPR, seroprotection rate; SCR, seroconversion rate; TIV, trivalent inactivated influenza vaccine; SPR defined as proportion of subjects with HI antibody titers $\geq 1:40$; SCR defined as proportion of subjects with a pre-vaccination HI antibody titer $< 1:10$ and post-vaccination HI antibody titer $\geq 1:40$, or subjects with at least a 4-fold increase in the post-vaccination HI antibody titer. Age ranges refer to age at time of AS03-adjuvanted A(H1N1)pdm09 vaccination.